| CYFRA 21-1; LUNG CANCER MARKER, SERUM (ECLIA) | ng/mL | < 3.30 |

**Note:**

1. This test is not recommended for the primary diagnosis of Lung cancer.

2. In diagnosed cases of NSCLC, post treatment baseline samples should be followed by serial determinations at monthly intervals for assessing prognosis.

3. Patients receiving Biotin therapy in high doses should not be tested for at least 8 hours after the last dose.

4. Levels greater than 30 ng/mL are highly indicative of Primary Bronchial carcinoma.

**Clinical Use**

- Monitoring the course of Non-small cell lung cancer (NSCLC)
- Course monitoring in Myoinvasive Bladder cancer

**Increased Levels**

- Non-Small cell carcinoma lung
- Acute pneumonia
- Tuberculosis
- Interstitial lung disease
- Liver cirrhosis
- Renal failure